The effects of agomelatine in cisplatin-induced toxicity on the kidney and liver tissues
In vivo study
DOI:
https://doi.org/10.1590/s2175-97902022e20957Palavras-chave:
Agomelatine, Cisplatin, Nephrotoxicity, Hepatotoxicity, Oxidative stressResumo
Nephrotoxicity and hepatotoxicity are frequently seen adverse effects during cisplatin chemotherapy. In this study, we investigated the effects of agomelatine on cisplatin-induced toxicity in the kidney and liver. Animals were administered with a single dose of cisplatin (7 mg/kg, i.p.) and treated with agomelatine (20 and 40 mg/kg, p.o) for seven days. Renal and hepatic functions were evaluated by measuring concentrations of creatinine, BUN, AST and ALT in the serum. Oxidative stress and protein peroxidation were assessed by measuring SOD, CAT, GSH and AOPP levels in both tissues. Serum PON-1 levels were also evaluated. Histopathological analysis was performed to determined structural changes in the kidney and liver. Agomelatine (20 mg/kg) treatment approximately halved cisplatin-related increase in serum creatinine, BUN, AST and ALT levels. Agomelatine (20 mg/kg) significantly prevented the cisplatin-induced excessive decrease in SOD, CAT, GSH in both tissues and serum PON-1 levels. Agomelatine (20 and 40 mg/kg) protected the structural integrity of the kidney against cisplatin-insult. Although agomelatine (40 mg/kg) protected the kidney and showed parallel results with 20 mg/kg biochemically, it failed to show the same liver tissue effects in both analyses. Although agomelatine protected against cisplatin-induced toxicity in the kidney and liver, care should be taken with higher doses for possible hepatotoxicity.
Downloads
Referências
Aguiar CCT, Almeida AB, Araújo PVP, Vasconcelos GS, Chaves EMC, Do Vale OC, et al. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol. 2013;33(6):825-35.
Aygun H, Gul SS. Protective effect of melatonin and agomelatine on adriamycin-induced nephrotoxicity in rat model: A renal scintigraphy and biochemical study. Bratislava Med J. 2019;120(2):113-8.
Bilgic Y, Akbulut S, Aksungur Z, Erdemli ME, Ozhan O, Parlakpinar H, et al. Protective effect of dexpanthenol against cisplatin-induced hepatotoxicity. Exp Ther Med. 2018;16(5):4049-57.
Camps J, Marsillach J, Joven J. Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World J Gastroenterol. 2009;15(16):1929-33.
Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol. 2009;61(3):223-42.
Demirdaş A, Nazıroğlu M, Ünal GÖ. Agomelatine reduces brain, kidney and liver oxidative stress but increases plasma cytokine production in the rats with chronic mild stress-induced depression. Metab Brain Dis. 2016;31(6):1445-53.
Freiesleben SD, Furczyk K. A systematic review of agomelatine-induced liver injury. J Mol Psychiatry. 2015;3(1):4.
Galgamuwa R, Hardy K, Dahlstrom JE, Blackburn AC, Wium E, Rooke M, et al. Dichloroacetate prevents cisplatin-induced nephrotoxicity without compromising cisplatin anticancer properties. J Am Soc Nephrol. 2016;27(11):3331-44.
Ghadrdan E, Sadighi S, Ebrahimpour S, Abdollahi A, Hadjibabaei M, Gholami K, et al. The effect of melatonin on cisplatin-induced nephrotoxicity: A pilot, randomized, double-blinded, placebo-controlled clinical trial. Eur J Integr Med. 2020;34:101065.
Günaydın C, Avcı B, Bozkurt A, Önger ME, Balcı H, Bilge SS. Effects of agomelatine in rotenone-induced Parkinson’s disease in rats. Neurosci Lett. 2019;699:71-6.
Hajian S, Rafieian-Kopaei M, Nasri H. Renoprotective effects of antioxidants against cisplatin nephrotoxicity. J Nephropharmacol. 2014;3(2):39-42.
Kilic U, Kilic E, Tuzcu Z, Tuzcu M, Ozercan IH, Yilmaz O, et al. Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway. Nutr Metab. 2013;10(1):7.
Koyuncu I, Kocyigit A, Gonel A, Arslan E, Durgun M. The Protective Effect of Naringenin-Oxime on Cisplatin-Induced Toxicity in Rats. Biochem Res Int. 2017;2017:9478958.
Liao Y, Lu X, Lu C, Li G, Jin Y, Tang H. Selection of agents for prevention of cisplatin-induced hepatotoxicity. Pharmacol Res. 2008;57(2):125-31.
Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: Implication in arteriosclerosis diseases. N Am J Med Sci. 2012;4(11):523-32.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-75.
Lu Y, Cederbaum AI. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol Sci. 2006;89(2):515-23.
Masubuchi Y, Kawasaki M, Horie T. Down-regulation of hepatic cytochrome P450 enzymes associated with cisplatin-induced acute renal failure in male rats. Arch Toxicol. 2006;80(6):347-53.
Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954-64.
Montastruc F, Scotto S, Vaz IR, Guerra LN, Escudero A, Sáinz M, et al. Hepatotoxicity related to agomelatine and other new antidepressants: A case/noncase approach with information from the portuguese, French, Spanish, and Italian pharmacovigilance systems. J Clin Psychopharmacol. 2014;34(3):327-30.
Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014:967826.
Pladevall-Vila M, Pottegård A, Schink T, Reutfors J, Morros R, Poblador-Plou B, et al. Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources. CNS Drugs. 2019;33(4):383-95.
Şener G, Şatiroglu H, Kabasakal L, Arbak S, Öner S, Ercan F, et al. The protective effect of melatonin on cisplatin nephrotoxicity. Fundam Clin Pharmacol. 2000;14(6):553-60.
Soni H, Kaminski D, Gangaraju R, Adebiyi A. Cisplatin-induced oxidative stress stimulates renal fas ligand shedding. Ren Fail. 2018;40(1):314-22.
Sun CY, Nie J, Zheng ZL, Zhao J, Wu LM, Zhu Y, et al. Renoprotective effect of scutellarin on cisplatin-induced renal injury in mice: Impact on inflammation, apoptosis, and autophagy. Biomed Pharmacother. 2019;112:108647.
Weijl NI, Elsendoorn TJ, Lentjes EGWM, Hopman GD, Wipkink-Bakker A, Zwinderman AH, et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: A randomised, double-blind, placebo-controlled study. Eur J Cancer. 2004;40(11):1713-23.
Yigitturk G, Acara AC, Erbas O, Oltulu F, Yavasoglu NUK, Uysal A, et al. The antioxidant role of agomelatine and gallic acid on oxidative stress in STZ induced type I diabetic rat testes. Biomed Pharmacother . 2017;87:240-6.
Zhang L, Cooper AJL, Krasnikov BF, Xu H, Bubber P, Pinto JT, et al. Cisplatin-induced toxicity is associated with platinum deposition in mouse kidney mitochondria in vivo and with selective inactivation of the α-ketoglutarate dehydrogenase complex in LLC-PK1 cells. Biochemistry. 2006;45(29):8959-71.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
